NCT01913691 2019-12-17
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02489266 2017-07-27
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01851408 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00025051 2013-03-22
Celecoxib in Preventing Skin Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01216787 2013-01-31
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn